ABSTRACT Currently, some serious comorbidity-impacted chronic diseases have high incidence among older people in the U.S. Due to the incompleteness of the related clinical data, it is difficult to refine these diseases' staging and quantitatively assess risk effects of comorbidities on symptom progressions. Here, we used both electronic medical records (EMRs) and claims data to obtain a comprehensive data source in this paper. We adopted osteoarthritis (OA) as a demonstrated major disease. The key comorbidities and their risks for various OA stage-related progressions were estimated. We utilized the linked EMRclaims dataset of OA from 2007 to 2014. The EMR data provided pain scores and laboratory data, while claims data provided costs as a proxy for disease severity. Although both datasets contained diagnoses, procedures, and medications, the linked dataset included more distinct codes. We established a prototype to combine our developed relational dependency network (RDN) approach with Cox proportional models to extract and estimate key comorbidities' impacts on OA progression. We identified the key OA stage-related comorbidities. Our studies indicate that the combination of the EMR with claims data is a useful strategy for obtaining more accurate medical data sources from patients. The analyses of the impact of clinical factors on OA staging clarify the associations between key covariates and OA progression. These approaches can be generalized to summarize the impact of comorbidities on the development of various chronic diseases.
I. INTRODUCTION
Osteoarthritis (OA) is a degenerative joint disease, affecting over 30 million adults in the U.S [1] . In recent years, 33.6% of the population aged 65 and up in the United States have various types of OA [2] . Thus, there is an urgent need to develop effective mechanisms for the prevention and treatment of OA.
Some coexisting clinical conditions (i.e., diagnostic diseases, symptoms) have been known to play an important role in the development of OA [3] . The coexistent clinical factors condition is defined as comorbidities of OA [4] . Currently, most comorbidity-related OA studies focus on assessing the association between superficial OA symptoms and co-existing diseases [5] - [8] . Few studies have devoted to exploring the impact of comorbidities on OA progressions. Based on the etiopathogenesis, The associate editor coordinating the review of this manuscript and approving it for publication was Yonghong Peng.
OA's progression has been divided into 3 sequential stages, including mild, moderate and severe stages [9] . OA symptoms for various stages may be caused by specific comorbidities [10] - [12] . It is necessary to quantitatively estimate comorbidities' impacts.
The clinical data that we used in this study include the electronic medical records (EMR) in Wake Forest Translational Data Warehouse (TDW) and the claims dataset purchased from Centers for Medicare & Medicaid Services (CMS) [13] . TDW EMR data is an important resource for studying clinical oncology, epidemiology, and comparative effectiveness. However, it is difficult to share TDW EMR data across different institutions due to the privacy rule. Claims dataset contains cross-institutional information, whereas the included clinical factors are not enough for clarifying the pathogenesis of diseases. Here, we combined TDW EMR data with the claims data to overcome limitations for using either claims or TDW EMR dataset alone. We adopted the relational dependency networks (RDN) approach [14] to extract the core clinical factors related to various OA stages. RDN reflects the dependency direction and strength among relational clinical instances [15] . It can be applied to association analyses of numerous biomarkers and clinical factors, which are represented as instance elements. Biomedical big data have provided tremendous data sources for pathologic and clinical knowledge discovery. RDNs obtained by various association approaches can delineate different knowledge networks, which reflect disparate subcategories of clinical studies. In order to handle poor data quality issues such as missing values and heterogeneity [16] , we developed a novel RDN approach, named bootstrapping for unified feature association measurement (BUFAM) [17] . By applying BUFAM-RDN to the linked EMR-claims dataset, core clinical factors and association networks were derived. In addition, the relationship network among these extracted clinical factors was generated. We then did a risk analysis on these clinical factors and extracted the high-risk factors.
In our study, a prototype was established to extract and analyze key comorbidities' impacts on the stage progressions of the main disease. We combined our proposed association approach (BUFAM, bootstrapping for unified feature association measurement) with the classical risk estimation methodology (logistic, Cox proportional regression, and generalized linear model). The total pipeline is composed of 3 steps: (1) Construct Relational Dependency Network (RDN) through applying BUFAM to high-frequent clinical factors; (2) Based on the pathologic stage-related RDNs, generate new cox proportional regression and generalized linear models to summarize the high-frequent comorbidities' impacts (hazards and economic effects) on main disease's stage progression for collected patient records (training samples); (3) Predict the risks of stage changes and estimate disease stages for new patient records (testing samples). The 3 steps can be considered as a prototype to extract and analyze key comorbidities' impacts on the phase change of the main disease. We used Osteoarthritis (OA) as a demonstration case to estimate core comorbidities' effects. We have compared the results of our pipeline with those of traditional risk estimations on high-frequent clinical indices. It is evident that our pipeline can give new and reasonable discoveries related to comorbidities' effects. The prototype can be applied to any main disease with evident pathologic phases. For related physicians, our prediction models can provide the quantitative measurement of core symptoms' impacts on the stage progression of the main disease. Such estimation may guide clinicians' diagnosis and therapy decisions for personalized medicine.
II. MATERIALS AND METHODS

A. OVERVIEW OF EMR AND CLAIMS DATASET FOR OA 1) DATA SOURCE
The EMR data used in this study was from the i2b2-framework-based TDW [18] , including 5 tables depicting demographics, clinical visit records, detailed symptom and therapy notes, medical concepts and provider information. Medical concepts refer to detailed clinical terminologies related to diagnoses, procedures, medications and lab tests.
The claims data was purchased from CMS and contained OA cases collected during 2007∼2014. The original claims dataset [19] consisted of 27 tables belonging to 5 categories, including 14 tables for the Healthcare providers, 4 for the summarization of beneficiaries, 1 for the prescription drugs, 2 for durable medical equipment and 6 for hospices. Multiple healthcare institutes were covered in the claims notes.
2) STUDY COHORT
We collected OA patient data from 1,300,000 patients' TDW EMR data (2001 -2014) and 101,000 patients' claims data (2007 -2014) from the Wake Forest Baptist Medical Center and Translational Science Institute (CTSI).
TDW EMR data is only from one provider (Wake Forest Baptist Medical Center), while claims data is from multiple healthcare institutions. For lab test records, we can have access to the longitudinal notes in one institution during the censoring period (records over time). If the patient moves to another provider, we can trace his/her information of diagnoses, therapies, and medications. In general, the linked EMR-claims data can provide integral clinical information related to the specific patient over the censoring period.
In order to construct the linked EMR-claims dataset, we screened OA patients based on 2 prerequisites, including that (1) clinical records must be in both of the TDW EMR and claims datasets, and (2) the OA diagnosis records should appear at least once either in TDW EMR or the claims dataset during 2007 ∼ 2014. We determined the cohorts by analyzing TDW EMR and claims data independently and then extracted 8,480 patients with OA records in TDW EMR and claims data. During our censoring period (2007 ∼ 2014), 20,614 patients in TDW EMR had diagnosis records of OA (including different subcategories of OA such as knee OA, hip OA), while 8,480 patients had claims data. In addition, we obtained the patient ID mapping table between TDW EMR and claims data from Wake Forest Clinical and Translational Science Institute (CTSI).
Finally, the EMR and claims records of these 8,480 patients during 2007 ∼ 2014 were selected as our study cohort.
3) COVARIATES
Covariates refer to various medical terminologies, which own coded values reflecting the terminology-related medical concept and appear in The contents of claims data involved the medical costs, demographics, diagnosis, dispensing, procedures, encounter, and enrollment. OA symptoms were classified into leg OA, localized primary OA, and general OA, as shown in Figure1. The year 2007 was used as the baseline.
In Figure 1 , for the factors from both sources, we adopted the union set of clinical records. 
4) OUTCOMES
The primary outcome was OA-related diagnosis records (EMR and claims data), WOMAC pain scores (EMR) and various medical expenditures (claims data). The three outcomes are applied to the extraction of OA patients, OA staging and estimations of comorbidities' dynamic impacts on OA progressions.
5) STATISTICAL ANALYSIS
In order to extract reasonable clinical indices related to OA stages, we applied RDN to original medical records. RDN covered various association test approaches such as Spearman-test, One-way test, and Pearson correlation. Regarding the estimation of OA stages, we executed the logistic regression on candidate associated clinical characteristics. In addition, the Cox proportional regression was applied to the prediction of OA progression risks. Finally, we used the generalized linear model to both expenditure and clinical records for estimating the dynamic impacts of OA's comorbidities.
B. STAGING OF OA
The patients were first classified into mild, moderate and severe stages of OA using the Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain score, a standard measurement tool for knee and hip OA [20] . WOMAC scores are from the self-administered questionnaire consisting of 24 items for 3 subscales, including pain, stiffness and physical functions. The information of questionnaires is stored in EPIC system of Wake Forest Medical School. All contents in TDW EMR data are from Wake EPIC system. We extracted the questionnaire records from EPIC and summed the scores related to 3 subscale factors. The summed scores were considered as the WOMAC scores. With reference to the initial OA staging of individual patients, we calculated the average WOMAC score for each patient during the whole censoring period (2007 ∼ 2014). Based on the WOMAC scoring threshold, each patient was classified into a specific OA stage. The WOMAC scores between 0 and 1 represented two conditions at the mild stage (None and slight); the scores within 1 ∼ 3 for the moderate stage and those within 3 ∼ 4 for the severe stage (very and extremely). Of 8,480 OA patients, 4,313 patients were in the mild stage, 2,476 in the moderate stage, and 1,691 in the severe stage. VOLUME 7, 2019 Here, the average of annual WOMAC scores is a general approach for staging OA patients. Based on the limited WOMAC records in our TDW EMR data, the average of patients' WOMAC scores during the whole censoring period can generate the comparatively precise groups of patients related to 3 OA stages. If we only utilize WOMAC notes in shorter periods or adopt separate WOMAC information on specific dates, patients' OA staging will be less accurate. In addition, the patient number will be reduced because of the missing issue of WOMAC information in shorter periods.
C. CONSTRUCTION OF THE RDN GRAPH RELATED TO SPECIFIC OA STAGE
In OA-related study, we developed BUFAM (Bootstrapping for unified feature association measurement), which is an association analysis approach for pairwise clinical factors. BUFAM provides a uniform metric to enable an unbiased analysis of pairwise feature associations across datasets. Based on the different combinations of data types (numeric, binary, categorical, ordinal) related to clinical factors, BUFAM will select different statistical measurements (e.g., spearman, one-way, Chi-square test) to derive the association weights accurately. Furthermore, BUFAM can (1) deal with the data heterogeneity issue; (2) solve the multi-site harmonization; and (3) address the missing data problem [21] . Thus, BUFAM enables efficient and effective use of heterogeneous biomedical big data for reflecting clinical factors' associations and understanding diseases.
Based on the frequency distribution of clinical covariates, we selected 200 of the most frequently occurring factors and calculated the average value of each patient during the censoring period (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) . In general, numeric and ordinal factors are represented by algebra; while binary and subindexes of categorical factors are shown as occurrences. For a specific clinical covariate, if one patient does not share the related information, the element value of covariate-patient is NA. Thus, the matrix with the most frequent clinical factors was constructed. We then applied BUFAM-RDN to the matrix to obtain the pairwise associations and calculated the p-values between any two specific clinical factors. Based on the p-value threshold (0.01) and the presumed values of in-degree and out-degree for nodes (7), the significantly associated pairs were used as the nodes and edges in the final RDN graph.
Within the linked EMR-claims dataset, rare (lowfrequency) disease indices coexisting with OA are shared by few patients. There exist large numbers of NA values related to most patients, which make it impossible to apply BUFAM for constructing RDN. For choosing 200 most frequent features, we have checked the status of missing values in our dataset and observed that the missing data cases within 200 most frequent clinical factors can be handled by BUFAM. If more features are included, BUFAM will give less reliable estimations. We have tried other approaches such as the causality analysis (Partial causality, Granger causality). However, the missing data problem and multi-site harmonization cannot be solved well. BUFAM is more adaptive to the dataset with heterogeneity and missing record issues.
D. ESTIMATION OF OA STAGES USING THE LOGISTIC REGRESSION MODEL
WOMAC pain score has been used for the OA stage identification [22] . However, it is often inconvenient to obtain the related integral information [23] . This reflects the need to estimate the OA stages using non-WOMAC medical information. Since the WOMAC records are often incomplete, the OA stages cannot be accurately evaluated. However, we can apply a logistic regression model to the available clinical records to build a model for evaluating OA stages. Since the selected non-WOMAC clinical records are complete, we are able to construct the specific logistic regression model.
We estimated OA stages using clinical characteristics identified by RDNs. Since the data type of stage measurement is binary, we adopted the logistic regression model to estimate the probability of a particular OA stage. Three logistic models were constructed to estimate the likelihood of mild, moderate and severe stages, respectively. The input covariates are the demographic features and characteristics in the major modules of RDN. The output is a binary variable for identifying OA stage, which is derived from the index of pain measurement.
Generally, we utilized the standard logistic regression based on the principle of maximum likelihood. For model parameters, we guaranteed that the number of parameters was smaller than that of included patients (No. of coefficients < No. of observations). The order of selecting coefficients (clinical factors) conformed to the decreasing order of their appearance frequencies. In addition, we used the standard Newton-Raphson algorithm to extract specific coefficients (clinical factors) maximizing the likelihood of the data. Finally, the trained logistic model contained these selected coefficients. For the calibration of our models, the standard logistic regression returns well-calibrated predictions by default as it directly optimizes log-loss, which means the automatic calibration to fit the training data. We divided the patients of each stage into derivation and validation cohorts using 10-fold cross-validation strategy (see Table 2 ). Then, the 10-fold results were averaged to produce final estimations. We estimated two types of evaluation indexes, including (1) observed ratio and predicted risk probability ( Figure 3) ; and (2) sensitivity & specificity ( Table 4 )) The vertical axis of Figure 3 represents the portion of patients classified into a specific phase among all 3 stages. Figure 3 is composed of 3 parts related to 3 subcategories of OA. We used 3 logistic models to analyze the same patient's data and obtained 3 risk probabilities corresponding to the OA stages. The resulting highest risk probability was used to classify patients into a specific OA stage. (1), we adopted the annual average WOMAC score and expenditure summation as two OA-stage mapping indices. Then, through the WOMAC via OA stage transformation (Section ''Staging of OA'') and annual cost intervals for different OA stages, we derived the specific OA stage related to each patient in each year. For (2), we picked up the common regions (patient via year) between two OA stage tables (one derived from WOMAC transformations, another from cost transformations). Then based on the identification of the first consecutive year area and the changing pattern of disease stages, we assigned each related patient to one of 4 stage change cases.
The Cox proportional regression model was employed to estimate the risk of OA stage changes. The outcomes (events) were four cases. Referring to the input covariates ''duration time'' and ''risk factor'', the duration time (until OA stage changes) was obtained through analyzing time series data of each patient, while the risk factors were the 10 most frequently co-occurring characteristics as shown in Table 3 . Our monitored comorbidities for the source stages of 4 cases are originated from the high-frequent co-existing diseases or treatments in Table 3 . For instance, in Case 1 (Mild OA − > Moderate OA), the source stage is Mild. Then, the results related to Case 1 involve all 10 high-frequent comorbidities related to Mild stage in Table 3 . We monitored the ten comorbidities' risks on the OA stage progression towards Moderate stage.
To reflect the dynamic effect of key comorbidities on OA progression, we applied a generalized linear model (GLM) to calculating covariates' coefficients for every year [25] . Here, ''dynamic effect'' means the tendency of comorbidities' impact changes among different years. It measures the trend of comorbidities' impacts on OA stage progressions. The outcome of GLM is the clinical expenditure, an indirect reflection of OA severity levels.
We calculated annual expenditures for each patient. The payments were involved in the diagnosis, procedure and dispensing drugs. For each patient, we summed all costs related to both self-burdened and insurance reimbursed portions in each year during the censoring period. The average annual total costs for the specific patient were then calculated. Based on the classified patient cohorts associated with 3 OA stages, we performed a Kruskal-Wallis test on the average annual expenditures for 3 groups of patients. ''Kruskal-Wallis'' test is a non-parametric approach for testing whether samples originate from the same distribution [26] . It can be used for comparing multiple independent sample sets with different sample sizes. Here, we adopt the ''Kruskal-Wallis'' test to check whether there exist evident differences among the expenditures related to patients for 3 OA stages. The returned p-value is 0.0426, which reflects that there exist evident differences among the expenditures for 3 OA stage-related patient groups. So there exist evident annual cost differences among the patients with different OA stages. Finally, we checked the annual payment range for each patient cohort; $677.38 ± 269.26 for Mild-stage cohort, $2348.61 ± 504.12 for Moderate-stage cohort, and $5648.20 ± 1632.58 for Severe-stage cohort. Therefore, Severe OA patients spent more than mild and moderate OA patients. In our GLM, ''comorbidity'' is regarded as covariates associated with the change of OA stages. Figure 6 reflects the comorbidity impacts on OA stage changes. Here, we clarify how to apply comorbidity indices to our GLM. High-risk comorbidities derived by the Cox proportional model (shown in Figure 4 ) are regarded as input covariates in GLM. The coefficients related to comorbidities represent the association between the OA stage and specific comorbidities. This provides some quantitative clues for physicians to analyze the comorbidity-related OA stage transformation. We provided some co-existing diseases and symptoms as candidate factors. In this way, physicians can narrow down the clinical covariates affecting OA status progression. In addition, earlier studies [27] , [28] have shown evidence that some diseases (e.g. Obesity, hypertension) aggravate the deterioration of OA stages. Our study provides a quantitative measurement of aggravation levels.
III. RESULTS
A. ESTABLISHMENT OF THE SPECIFIC NETWORKS FOR VARIOUS STAGES OF OA USING RDN APPROACHES
Three association network graphs for each OA stage were obtained. Four types of features are displayed in Figure 2 , including diagnosis (circle), procedure (diamond), diagnosisrelated group (DRG; hexagon) and dispensing (square). Figure 2A , 2B & 2C show RDN modules for mild, moderate and severe OA stage, respectively.
Through the network analysis of 3 OA stages, we narrowed down the key covariates. Here, our network analysis referred to the calculation of the in-degree and outdegree for each node. In Figure 2 , the nodes with summation values of in-degree and out-degree larger than the specific thresholds were considered as the harbor nodes (Thresholds: Figure 2A & 2B: 7; Figure 2C : 5). In addition, we did the modularity analysis for the networks in Figure 2A and 2B. There existed 3 modules in both networks. We checked the harbor nodes belonging to the major module (including most nodes in the entire network) and summarized their clinical meanings and categories, which helped us to narrow down the key covariates. Based on these analyses, the blood-related diseases (i.e., Hypertension, hyperlipidemia) were common in the mild and moderate OA stages, while respiratory diseases & various pain symptoms were associated with the severe stage. In addition, the major modules of RDNs provided candidate covariates for risk estimations of OA stages and onset processes.
B. RISK ESTIMATION OF OA STAGE
We assessed the sensitivity and specificity of the estimated OA stages using logistic models. Since the output is binary, a measurement of performing a binary classification test is needed. Sensitivity and specificity analysis is such the statistical measurement. Thus, we adopted the sensitivity and specificity to evaluate the performance of logistic models. For a specific patient, we applied his/her clinical records to 3 trained logistic models for 3 OA stages. Then, 3 probability values were outputs related to 3 OA stages. The predicted probability threshold was 0.6 (empirical value). The OA stage with the probability value larger than 0.6 and the maximum value among 3 probabilities was assigned to this patient. Here, the threshold is an optional parameter for determining OA stages. The probabilities greater than the threshold can strengthen the reliability of OA stage predictions. Furthermore, the index ''AUC'' was also calculated. We firstly constructed the ROC curves for our 9 logistic classifiers related to 9 columns in Table 4 . We set 10 discrimination thresholds for all samples and calculated the true positive rate (TPR) and false positive rate (FPR) related to each threshold. ROC curves were composed of these points (TPR & FPR). Then, AUCs were calculated related to 9 ROC curves. The related results were displayed in Table 4 and Figure 3 . As shown in Table 4 , the sensitivity and specificity are greater than 0.7 in 13 out of 18 testing items, indicating that the prediction from our model is reliable. However, we observe a large gap between the sensitivity and specificity values related to 3 OA cases (General OA Moderate, leg OA Mild, leg OA Moderate), indicating poor estimation performance. The likely cause is that the three OA cases have fewer training samples than other OA cases. In addition, RDN-derived candidate clinical factors may be less accurate due to the small sample status. With 9 OA cases showing in Table 4 , logistic regressions can generally provide the reasonable estimation of OA stages. Figure 3 shows the comparison between the ratio of observed stage-related patient numbers and that of predicted ones. Seven out of nine groups have a deviation of less than 10%. A 15% deviation was observed for the groups with mild and moderate stages of leg OA. Our results indicate that the logistic regression model can reliably estimate OA stages. Figure 4 shows the hazard ratios of various covariates for the derivation cohort for 4 cases. A hazard ratio larger than 1 represents a higher risk (positive association), while the hazard ratio less than 1 means a lower risk FIGURE 3. Ratios of observed and predicted patient numbers related to mild, moderate and severe stages for 3 subcategories of OA. Osteoarthrosis NOS-unspecific, Osteoarthrosis NOS-l/leg and localized Osteoarthrosis NOS-l/leg are 3 subcategories of Osteoarthritis (OA). The ratio of estimated patient numbers for mild, moderate and severe stages related to each subcategory of OA is calculated. Red points show the observed patient ratio, while green ones give the predicted ratios.
C. THE KEY COMORBIDITIES ASSOCIATED WITH OA PROGRESSION
(inverse associations) [29] . The effects of various covariates on OA progression are listed in Figure 4 . Red bars represent the high-risk covariates.
To validate the Cox proportional models, we grasped the patients in the validation cohort as described in Table 3 ) are shown in the bar-plots. Red bars represent high-risk clinical factors, while blue bars show ordinary covariates.
the Section ''Summarization of comorbidity hazards on osteoarthritis progression''. For each of 4 cases, we adopted the same covariates as the derivation cohort and applied the trained Cox proportional model to estimating the risks (risk = hazard/(1+hazard), range: 0 ∼ 1) (Each covariate [30] in the observed risks were calculated using Kaplan-Meier estimator [31] .
The observed ratio is extracted from K-M analysis, while the predicted risk probability is calculated based on hazard ratios. The estimated and observed risks are shown in Figure 5 . It is evident that the curves of predicted risk probabilities are close to those of observed ratios in all 4 cases. In addition, we calculate the average relative errors (Equation (1)) for 4 cases.
Pr risk : predicted risk probability, Pr observ : observed ratio. Case 1: 3%, Case 2: 4%, Case 3: 5%, Case 4: 5%. Based on the curve comparison and relative errors, our prediction model is comparatively reliable. 
E. RISK ESTIMATION OF COMORBIDITIES WITHOUT RDN
Regarding the effect evaluation of RDN, we applied partial correlation [32] and adjusted cosine similarity [33] , [34] to the feature selection. Meanwhile, the direct utilization of original clinical features was also adopted. After that, Cox proportional and logistic regressions were applied to the comorbidity estimation. categories only refer to ''diagnosis''. There are no ''procedure'', ''DRG'' and ''dispensing medication'' indicating that these feature selection methods lead to the biased acquisition of clinical information.
Based on these clinical indices, the comorbidity risks and OA stages were estimated by Cox proportional hazard and logistic regression models. The panel B in Figure 7 , 8 and 9 displays the impact of comorbidities on OA stage changes. We identified fewer clinical characteristics with hazards greater than 1 (red bars), which means that these comorbidities have an impact on OA progressions. For OA stage predictions, the panel C of Figure 7 , 8 and 9 displays the sensitivity and specificity analysis results related to different stages for 3 types of OA. Regarding Table 4 (estimations based on features extracted by RDN), these feature selection methods give much lower statistical values which represent unreliable predictions.
We also delineated the association networks of clinical indices derived by the three feature selection methods. In contrast, the size of RDN is larger than others. Meanwhile, the features in RDN refer to more clinical categories (diagnosis, procedure, DRG and dispensing). In addition, some associated indices in RDN were reported previously in the OA-related literature [5] , [35] , [36] . Therefore, RDN generates more reasonable clinical indices association networks.
In summary, our RDN-based pipeline can provide new and reasonable findings related to the impact of comorbidities on OA stage changes. RDNs extract representative co-existing diseases related to each of OA stages (Figure 2) . Then, our new Cox proportional models derive core comorbidities affecting OA stage progressions (Figure 4 ). For the estimation of OA stages, our combined logistic models can provide reliable and reasonable predictions for specific stages (Table 4) .
IV. DISCUSSION
Our approach pipeline is suitable for estimating comorbidities' impacts on the main disease with evident pathological stages. There exist numerous diseases with clear clinical phases such as Osteoarthritis, Chronic Kidney Disease, and Parkinson Disease. In addition, some co-existing diseases often play important roles in stage progressions (relief or aggravation). Through monitoring the status of comorbidities, the stages of the main disease can be estimated. Such practice is useful when it is inconvenient to measure the phases of the main disease. The accurate identification of disease stages will guide the medication or therapy decisions of related physicians (or clinical specialists).
The combined EMR-claims dataset provides a comprehensive data source for longitudinal tracing patients' clinical records in multiple healthcare institutions. Utilizing only TDW EMR data of one clinic may lead to the deficiency of complete diagnosis information, which brings tremendous missing values for important clinical factors. The estimation of OA staging, risk analyses and predictions of OA comorbidities will be unavailable or inaccurate. Using only claims data in different medical institutions will bring the loss of lab test results and some detailed symptom information. In addition, claims data does not include OA stage-related indexes (e.g. WOMAC). So the combination of TDW EMR with claims data can guarantee the integrity of medical records for specific patients during the censoring period. Based on the linked EMR-claims dataset, our current results are effective and reliable. Furthermore, we also tried to construct RDN by only using TDW EMR or claims dataset. The network size is evidently smaller than the present results. The corresponding clinical factors are incomplete. Therefore, the combination of TDW EMR and claims data can benefit the estimation of key comorbidities related to OA progression.
Our methodology can be summarized into 3 steps (Shown in Section ''Introduction''). The 3 steps can be considered as a prototype to extract and analyze key comorbidities' impacts on the phase changes of the main disease. Through choosing specific statistical tests, BUFAM can flexibly handle the pairwise feature associations with various combinations among main data types (numeric, binary, categorical, ordinal). Cox proportional regression and GLM are combined to generate the prediction model of comorbidity risks and impacts on main disease progressions. In general, our prototype combines our proposed association analysis and classical risk estimation strategies. For the new patients' structural medical records, core comorbidities will be extracted accurately. Meanwhile, the related risks and effects can be analyzed exhaustively.
Referring to selecting association approaches for pairwise clinical features, we have tried the Pearson correlation previously. It shows that the Pearson correlation is more adaptive to numeric features. If the data types of two features are both numeric, Pearson correlation is a good choice. However, for other data types such as categorical, ordinal and binary, Pearson's performance is weaker than other statistical measurements (e.g. Spearman, one-way or chi-square test). Based on different combinations of data types, we have summarized the best association statistical tests in our BUFAM [17] . In our study, the association approaches are automatically selected by BUFAM based on the data types of pairwise clinical features.
The linked EMR-claims data density has impacts on RDNs. High-frequent clinical factors can help to generate more accurate RDNs. We selected 200 most frequently occurring factors for each patient on average. In this way, the appearance frequencies of specific clinical features are similar in most patients, which decreased the missing data's impacts on deriving RDNs.
For some cases, our pipeline is not suitable for the diseases with rapid progressions and low influences of comorbidities. Our framework is helpful to estimate comorbidities' impacts on the main disease with multiple co-existing symptoms and provide quantitative risk predictions related to the pathological stage progressions. Based on these estimations, physicians may make preventive or therapeutic plans for individual patients.
During the whole project, we have communicated with one of Rheumatology (Bursitis, Arthritis, Osteoarthritis) physicians in Wake Forest Baptist Medical Center. He confirmed some comorbidity impacts on the aggravation of OA symptoms such as Hypertension and Obesity. In addition, we have checked two literature related to comorbidities' frequency and impacts on pain and physical functions [37] , [38] . Hypertension, dyslipidemia, obesity and ischaemic heart disease were reported as important comorbidities in general clinical practices, which match our partial results.
V. CONCLUSION
Our studies indicate that the combination of the EMR with claims data is a useful strategy for obtaining more accurate medical data sources from patients. The disease stagedependent association networks, derived by RDNs, objectively reflect the detailed pathology of disease stages. Our analyses of the effects of clinical factors on OA staging clarify the associations between key covariates and OA progression. The prototype of risk estimations for comorbidities can be applied to any disease with evident pathological stages and comorbidity impacts.
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